Search results for " Calcitonin Gene-Related Peptide"

showing 4 items of 4 documents

Triptans and CGRP blockade - impact on the cranial vasculature.

2017

Abstract The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and mig…

0301 basic medicineMigraine DisordersCalcitonin gene related peptide – CGRPNeuropeptidelcsh:MedicineMigraine modelsReviewTriptansReview ArticleCalcitonin gene-related peptide03 medical and health sciences0302 clinical medicineJournal ArticlemedicineHumansMigraine treatmentReceptorbusiness.industryTriptans Calcitonin gene related peptide – CGRP Anti-CGRP (receptor) monoclonal antibodies – mAbs Middle meningeal artery Middle cerebral arteries Migraine models Magnetic resonance angiography (MRA)Anti-CGRP (receptor) monoclonal antibodies – mAbsTrigeminovascular systemlcsh:RTriptansGeneral MedicineMiddle meningeal arterymedicine.diseaseTryptamines3. Good healthMagnetic resonance angiography (MRA)Middle cerebral arteries030104 developmental biologyAnesthesiology and Pain MedicineMigraineAnesthesiaNeurology (clinical)SerotoninbusinessNeuroscience030217 neurology & neurosurgerymedicine.drugReceptors Calcitonin Gene-Related PeptideThe journal of headache and pain
researchProduct

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus.

2020

An increased calcitonin serum level is suggestive of a medullary thyroid cancer (MTC), but is not pathognomonic. The possibility of false positives or other calcitonin-secreting neuroendocrine neoplasms (NENs) should be considered. Serum calcitonin levels are generally assessed by immunoradiometric and chemiluminescent assays with high sensitivity and specificity; however, slightly moderately elevated levels could be attributable to various confounding factors. Calcitonin values >100 pg/mL are strongly suspicious of malignancy, whereas in patients with moderately elevated values (10–100 pg/mL) a stimulation test may be applied to improve diagnostic accuracy. Although the standard protoco…

MalediagnosisEndocrinology Diabetes and Metabolismbiomarkers; tumor; calcitonin; calcitonin gene-related peptide; carcinoma neuroendocrine; diagnosis differential; endocrine gland neoplasms; false positive reactions; female; humans; janus kinases; male; middle aged; reference values; sensitivity and specificity; thyroid neoplasmscarcinoma0302 clinical medicineEndocrinologyReference ValuehumansEndocrine Gland NeoplasmThyroidMedullary thyroid cancerGeneral MedicineFalse Positive Reactionreference valuesMiddle Agedmedicine.anatomical_structure030220 oncology & carcinogenesisFemalehormones hormone substitutes and hormone antagonistsHumanThyroid nodulesCalcitoninmedicine.medical_specialtytumordifferentialCalcitonin Gene-Related Peptide030209 endocrinology & metabolismNeuroendocrinologySensitivity and SpecificityDiagnosis Differential03 medical and health sciencesInternal medicinemedicineBiomarkers TumorneuroendocrineThyroid NeoplasmsCalcitonin Measurementbusiness.industryfalse positive reactionsbiomarkersCalcitonin secretionmedicine.diseaseCarcinoma NeuroendocrineEndocrinologyCalcitoninjanus kinasesJanus KinaseDifferential diagnosisendocrine gland neoplasmsbusiness
researchProduct

Calcitonin gene-related peptide partly protects cultured smooth muscle cells from apoptosis induced by an oxidative stress via activation of ERK1/2 M…

2003

Abstract Oxidative stress induced by a glucose/glucose oxidase (G/GO) generator system dose-dependently decreased the viability of cultured vascular smooth muscle cells (VSMC) as estimated by MTT assay. Cell death was induced in 40% of cells exposed to 0.2 IU/ml of the free radical generating mixture. Annexin-V labeling, Hoechst staining together with DNA laddering demonstrated that apoptosis was responsible for this cell loss. Pretreatment of the cells with 10−8 M calcitonin gene-related peptide (CGRP) significantly attenuated the damaging effect of the oxidative stress. Indeed, cell viability was estimated to be 80% in CGRP-treated group, instead of 60% in absence of CGRP treatment. This …

Programmed cell deathVascular smooth musclep38 mitogen-activated protein kinasesCalcitonin Gene-Related PeptideMyocytes Smooth MuscleApoptosisBiologyDNA ladderingCalcitonin gene-related peptidemedicine.disease_causeProtective AgentsMuscle Smooth VascularmedicineAnimalsHumansCGRPViability assayRats WistarMolecular BiologyCells CulturedMitogen-Activated Protein Kinase 3integumentary systemSAPKCell BiologyHydrogen PeroxideMAPKMolecular biologyRatsUp-RegulationNeuropeptideOxidative StressMitogen-activated protein kinaseVascular smooth muscle cellbiology.proteinMitogen-Activated Protein KinasesOxidative stressReceptors Calcitonin Gene-Related PeptideSignal TransductionBiochimica et biophysica acta
researchProduct

Salivary and serum levels of substance p, neurokinin A and calcitonin gene related peptide in burning mouth syndrome

2009

Background: Burning mouth syndrome (BMS) is an enigmatic condition with the etiopathogenesis remaining largely obscure. However, a neuropathic basis for BMS continues to be an area of active clinical and research interest. Aim: It is becoming increasingly evident that certain oral disorders may be modulated by imbalances in certain neuropeptides such as substance P (SP), neurokinin A (NKA) and calcitonin gene-related peptide (CGRP) therefore we measured SP, NKA and CGRP in the saliva and sera of BMS patients as well as controls. Subjects and Methods: Salivary and serum SP, NKA and CGRP were determined in the 26 female patients with burning mouth syndrome (age range 51-78, mean 65.69 yrs), a…

Malemedicine.medical_specialtySalivaCalcitonin Gene-Related PeptideNeurokinin ANeuropeptideSubstance PBurning Mouth SyndromeCalcitonin gene-related peptideSubstance Pchemistry.chemical_compoundInternal medicinemedicineHumansSalivaGeneral DentistryAgedbusiness.industryDopaminergicBurning mouth syndromeMiddle Agedrespiratory system:CIENCIAS MÉDICAS [UNESCO]stomatognathic diseasesEndocrinologyOtorhinolaryngologychemistryCalcitoninUNESCO::CIENCIAS MÉDICASSubstance P ; neurokinin A ; calcitonin gene-related peptide ; burning mouth syndromeSurgeryFemaleNeurokinin Amedicine.symptombusiness
researchProduct